Skip to content

ImmunityBio, Inc. IBRX Proceeds from secured term loan

Proceeds from secured term loan at other companies

Tetra Tech logo
Tetra TechTTEK
$170M+36.0%
Pool Corporation logo
Pool CorporationPOOL
$173.4M-16.4%
Eagle Materials logo
Eagle MaterialsEXP
$0-100%
Allegro MicroSystems, Inc. logo
Allegro MicroSystems, Inc.ALGM
$0+100%
Insulet logo
InsuletPODD
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$75M

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSecuredDebt.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s proceeds from secured term loan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s proceeds from secured term loan?
ImmunityBio, Inc. (IBRX) reported proceeds from secured term loan of $75M in Q1 2026.
What does proceeds from secured term loan mean?
Cash inflows resulting from the issuance of debt instruments backed by specific company assets. This metric highlights the company's ability to leverage its asset base to secure external financing.